Recipient RAS gene variants and renal allograft function

Transplantation
Jérôme NicodPaolo Ferrari

Abstract

Genetic variants of the renin-angiotensin system (RAS) have been implicated in the progression of native kidney diseases. A decreased long-term renal allograft function has also been associated with increased activity of RAS, which may be genetically determined. The effect of the angiotensinogen (AGT), angiotensin-converting enzyme (ACE), angiotensin type 1 receptor (AGT1R), and aldosterone synthase (CYP11B2) genotypes on renal function was investigated in 223 first-allograft recipients. Graft function was estimated by yearly determinations of serum creatinine. Genotyping was performed for the M235T-AGT, the I/D-ACE, the A1166C-AGT1R, and the -344T/C-CYP11B2 gene polymorphisms using polymerase chain reaction. The percentage of patients with preserved stable graft function up to 15 years after transplantation was higher when mean blood pressure was <97 mmHg, than when it was >117 mmHg (60 vs. 25% of patients). The CYP11B2 genotype predicted long-term stable graft function with more patients suffering from worsening renal function with the CYP11B2 TT than the CC genotype (P=0.002). There was a weak association between the AGT1R genotype (P=0.037), but not the AGT or ACE genotypes, and a preserved long-term graft function. Cox pro...Continue Reading

References

Oct 2, 1992·Cell·X JeunemaitreJ M Lalouel
Jul 1, 1991·American Journal of Hypertension·M BrestickerB Anderson
Aug 1, 1991·Journal of the American Society of Nephrology : JASN·B D Myers, L Newton
Sep 13, 1990·The New England Journal of Medicine·U ScherrerR G Victor
Oct 25, 1985·The American Journal of Medicine·W A Katz
Sep 27, 1985·The American Journal of Medicine·L Raij, W F Keane
Jan 19, 1984·The New England Journal of Medicine·R M MerionR Y Calne
Aug 1, 1996·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·J BeigeA M Sharma
Aug 1, 1997·Journal of the American Society of Nephrology : JASN·J BeigeA M Sharma
May 20, 1998·The American Journal of Cardiology·Z A AbbudJ B Kostis
Jun 19, 1998·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·S HariharanM B Adams
Nov 10, 1998·Journal of the American Society of Nephrology : JASN·E GuidiG Bianchi
Feb 9, 2000·JAMA : the Journal of the American Medical Association·K C MangeH I Feldman

❮ Previous
Next ❯

Citations

Jul 18, 2008·Transplantation Reviews·Bernd KrügerBarbara T Murphy
Jun 27, 2006·Transplantation Proceedings·P M BiselliE C Pavarino-Bertelli
May 14, 2004·American Journal of Physiology. Renal Physiology·Fatemeh FouladkouOlivier Staub
Feb 14, 2003·Current Opinion in Urology·Brad MarderBarbara Murphy

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.